{"id":"rondecabtagene-autoleucel","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL4594309","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug involves ex vivo transduction of autologous T cells with a lentiviral vector encoding a CAR construct. The CAR-T cells are expanded and reinfused into the patient, where they recognize and eliminate tumor cells expressing the target antigen. This approach harnesses the patient's own immune system for durable anti-tumor activity.","oneSentence":"Rondecabtagene autoleucel is a CAR-T cell therapy that genetically modifies a patient's own T cells to express a chimeric antigen receptor targeting a tumor-associated antigen, enabling the engineered cells to recognize and kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:37.334Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer (Phase 3)"},{"name":"Ovarian cancer (Phase 3)"}]},"trialDetails":[{"nctId":"NCT07188558","phase":"PHASE3","title":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2026-01-12","conditions":"Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LYL314"],"phase":"phase_3","status":"active","brandName":"rondecabtagene autoleucel","genericName":"rondecabtagene autoleucel","companyName":"Lyell Immunopharma, Inc.","companyId":"lyell-immunopharma-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Rondecabtagene autoleucel is a gene-based CAR T-cell therapy used to treat various conditions, including Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, and Non-Hodgkin Lymphoma. It is being investigated in a Phase 3 clinical trial, comparing it to investigator's choice CD19 CAR T-cell therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}